他在一位肾移植患者移植六年后，停用了所有免疫抑制药物，包括可的松；六周后，移植肾工作得更有效率，GFR 更好（被呈现为 Tayebat 体系的一项成功）。
原始表述
هي كلمه واحده انا هقولها معايا حاله زرع ك بطلت لها ادويه مثبطات المناعه بتاعتها الكورتيزون بعد ست سنين من الزرع بتاعها والحمد لله بعد شهر ونص الكليه المزروعه بتعمل بكفاءه اكتر الكليات من احسن والجي اف ار احسن بفضل الله
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
他在一位肾移植患者移植六年后，停用了所有免疫抑制药物，包括可的松；六周后，移植肾工作得更有效率，GFR 更好（被呈现为 Tayebat 体系的一项成功）。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr.D Clinics - Diaa Al Awady is live! الام الذبحة و التهاب الأعصاب الطرفية (打开来源)
- 发布日期
- 2025年2月18日
- 时间戳
- 0:18:45 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Transcript is YouTube CC or machine-generated (no timestamps); wording may contain speech-recognition errors. Speaker attribution within live streams/podcasts is not marked in the transcript; the excerpt was judged to be Elawady's own speech from context. Recurrence = number of archive transcripts matching the keyword pattern ['زرع|زرعه|المزروعه', 'مثبطات|بروجراف|ماي فورتك|ادويه المناعه|دوا الزرع'] (approximate; includes re-uploads/clips; 11 distinct text passages).
- 所声称的机制
Not stated in this excerpt.
- 所声称的健康影响
Improved function of a transplanted kidney after stopping immunosuppression.
- 涉及人群
Kidney-transplant recipients.
- Elawady 设定的地域限制
none found; he does not limit this statement to a country or to a production system
来源版本存在差异
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- انت نازل الارض تجمع حسنات والا تقضي عقوبه ؟ #ضياء_العوضي #الحقيقة_والسراب (打开来源)
- 发布日期
- 2025年12月16日
- 时间戳
- 无（转录文本不含时间信息）
- 归属的不确定性
- Further video in which the same statement recurs; no excerpt recorded. Archive transcript without timestamps.
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live!لايف الخميس ❤️❤️❤️ (打开来源)
- 发布日期
- 2026年1月30日
- 时间戳
- 无（转录文本不含时间信息）
- 归属的不确定性
- Further video in which the same statement recurs; no excerpt recorded. Archive transcript without timestamps.
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live!تجويع الخلايا من السكر الكظرية (打开来源)
- 发布日期
- 2025年10月26日
- 时间戳
- 无（转录文本不含时间信息）
- 归属的不确定性
- Further video in which the same statement recurs; no excerpt recorded. Archive transcript without timestamps.
科学评估
错误 – 该说法与可靠证据相矛盾。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
He reports that he stopped all immunosuppressants and cortisone in a kidney-transplant recipient six years after transplantation and that six weeks later the graft worked better.
2. 哪些内容可证实是正确的？
Corticosteroids can be withdrawn in selected recipients when other immunosuppressants continue: in a blinded RCT, early steroid withdrawal with continued tacrolimus and MMF gave similar 5-year graft survival and function and better metabolic outcomes, though with more mild acute rejection (17.8% vs 10.8%) (I-INTB-10). He also said himself that he did not know what would happen. A Cochrane review updated in 2026 (53 trials) found no clear difference in graft loss in the first year when steroids were stopped or avoided while other drugs continued (I-SRC-101). A small number of recipients do keep a working kidney without any drugs (operational tolerance), but this is rare, cannot be predicted by routine tests, and about 30% of such patients in a European cohort later showed slow loss of function (I-SRC-118).
3. 哪些内容是错误或夸大的？
Presenting this case as a success is not justified. Not taking immunosuppressants is common and is associated with about seven times higher odds of graft failure; a median 36% of graft losses followed prior nonadherence (I-INTB-09). Rejection can develop months after stopping drugs, so six weeks says little. A short-term rise in GFR after stopping calcineurin inhibitors (tacrolimus, ciclosporin) is expected: the KDIGO guideline notes that randomised trials of complete calcineurin-inhibitor withdrawal show some small benefit in graft function but significantly more acute rejection (I-INTB-11), so a better GFR does not prove the graft is safe. In the CTOT-09 trial, stopping tacrolimus even in low-risk recipients led to rejection in 4 of 14 and new donor-specific antibodies in 5 of 14, and the trial was stopped (I-SRC-102). Immunosuppression and graft monitoring are part of standard transplant care (I-INTB-11).
4. 哪些内容仍不明确？
What happened to this patient later is unknown.
5. 哪些研究支持该说法？
I-INTB-10 and I-SRC-101 (only for steroid withdrawal with continued immunosuppression); I-SRC-118 (rare operational tolerance; selected survivors).
6. 哪些研究与该说法相矛盾？
7. 对德国和欧洲而言情况如何？
Transplant centres in Europe follow KDIGO-type guidance; changes in immunosuppression are made by the transplant team.
8. 关于埃及的已知情况是什么？
The same applies in Egypt; graft loss means a return to dialysis.
9. 合理的实际结论是什么？
未经移植团队同意，切勿停用移植药物。有时可以减少类固醇，但只能在专科医生监督和监测下进行。
评估详情
- 证据确定性的依据
The single case cannot be verified and six weeks is far too short to judge graft survival. Systematic review evidence shows that not taking immunosuppressants raises the odds of graft failure about sevenfold (I-INTB-09). Complete withdrawal has not been tested in randomised trials (it would be unethical), so certainty is moderate rather than high. Since the last review, a randomised trial (CTOT-09, I-SRC-102) showed that stopping only tacrolimus in carefully selected low-risk recipients caused rejection or new donor-specific antibodies in about a third, and the KDIGO guideline text confirms that RCTs of calcineurin-inhibitor withdrawal show a small gain in graft function but significantly more acute rejection.
- 来源质量
Machine transcript of a live stream; wording may contain recognition errors; meaning checked in context. Anecdote; no medical records shown.
- 地区可推广性
Universal transplant immunology.
- 个体例外情况
A small minority of recipients may become tolerant of the graft (general transplant knowledge, not sourced here); this cannot be predicted without specialist testing.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。
研究问题: In kidney-transplant recipients several years after transplantation, does stopping all immunosuppressive drugs (including corticosteroids) preserve or improve graft function compared with continuing maintenance immunosuppression?
研究问题详解 (PICO)
- 人群
- Kidney-transplant recipients on maintenance immunosuppression (years after transplantation)
- 干预或暴露
- Withdrawal of all immunosuppressants and corticosteroids (or of single key drugs)
- 对照
- Continued maintenance immunosuppression
- 地域范围
- universal biology; transplant care standards are international and apply in Egypt
- 结局指标
- Acute rejection
- De novo donor-specific antibodies
- Graft loss / return to dialysis
- GFR (short and long term)
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
A few kidney recipients keep working kidneys without drugs
Brouard S et al.. Am J Transplant 2012 · PMID 22974211 · DOI 10.1111/j.1600-6143.2012.04249.x 病例系列 / 病例报告已核查摘要新增A European cohort of 27 kidney recipients who kept working grafts after stopping all immunosuppression.
- 实际结果
- 19 of 27 stable at mean 9 ± 4 years; 30% slowly deteriorated; DSA-associated injury in half of biopsied patients.
- 方法学质量
- low (selected survivors, no denominator)
- 相关性
- direct for the existence of rare tolerance
- 局限
- Counts only successes; cannot estimate how often stopping is tolerated.
Stopping steroids after a kidney transplant while other anti-rejection drugs continue
Oliveras L et al.. Cochrane Database Syst Rev 2026 · PMID 42187003 · DOI 10.1002/14651858.CD005632.pub4 Meta分析已核查摘要新增Cochrane 2026: steroid withdrawal or avoidance while other drugs continue.
- 实际结果
- Graft loss <=1 y withdrawal RR 1.19 (0.72-1.96); BPAR avoidance RR 1.58 (1.11-2.25); less post-transplant diabetes.
- 方法学质量
- high (Cochrane, 53 RCTs; low-certainty evidence)
- 相关性
- indirect: only steroids stopped, other drugs continued
- 局限
- Does not test stopping all drugs.
哪些证据不支持该说法？
Stopping tacrolimus after kidney transplant caused rejection
CTOT-09 RCT: tacrolimus weaned in carefully selected immunologically quiescent recipients.
- 实际结果
- Stopped early: acute rejection 4/14, de novo DSA 5/14 in the withdrawal arm.
- 方法学质量
- moderate (randomised, small, stopped early)
- 相关性
- direct: withdrawal of the key drug years-scale after transplant
- 局限
- Small; one drug withdrawn.
Skipping transplant drugs often leads to losing the kidney
Butler JA et al.. Transplantation 2004 · PMID 15021846 · DOI 10.1097/01.tp.0000110408.83054.88 Meta分析已核查摘要Systematic review of non-adherence to immunosuppressants.
- 实际结果
- Non-adherence associated with about sevenfold odds of graft failure; median 36% of graft losses preceded by non-adherence.
- 方法学质量
- moderate (observational synthesis)
- 相关性
- direct for stopping drugs outside medical supervision
- 局限
- Observational.
International guideline for kidney-transplant care
KDIGO Transplant Work Group. Am J Transplant 2009 · PMID 19845597 · DOI 10.1111/j.1600-6143.2009.02834.x 指南 / 立场声明已核查摘要KDIGO 2009 transplant guideline (full PDF read for chapter 3).
- 实际结果
- Suggests CNIs and prednisone be continued rather than withdrawn (2B/2C); RCTs of complete CNI withdrawal (8 RCTs, 1891 patients) show a small benefit in graft function but significantly increased acute rejection.
- 方法学质量
- guideline, GRADE-based
- 相关性
- direct
- 局限
- 2009; update pending.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Continuing maintenance immunosuppression; only supervised steroid withdrawal in selected patients is supported.
为什么有些研究权重更大
Randomised data (CTOT-09; CNI-withdrawal RCTs summarised by KDIGO; Cochrane steroid review) and the non-adherence synthesis outweigh a single unverified anecdote with six weeks of follow-up. The tolerance cohort shows rare exceptions but counts only survivors.
因果关系是否已确立？ 很可能 Randomised withdrawal of a single key drug caused rejection and antibody formation; observational data link stopping drugs to graft failure. Complete withdrawal of all drugs has not been randomised (unethical), so causal evidence is from partial withdrawal plus consistent observational data.
仍存在的不确定性
Long-term outcome of the patient described is unknown; rare operationally tolerant recipients exist but cannot be identified reliably in advance.
合理的结论
Stopping all immunosuppression is expected to cause rejection and graft loss in most recipients. A rise in GFR shortly after stopping calcineurin inhibitors is a known drug effect (KDIGO: small benefit in graft function with CNI withdrawal) and does not show safety.
为什么研究结果看起来互相矛盾？
这是否取决于国家？
- 一般生物学效应
- Transplant immunology is universal.
- 饮食习惯
- Not diet-related.
- 食品原产地
- Not applicable.
- 污染物
- Not applicable.
- 本国生产条件
- Not applicable.
- 法律规则
- Immunosuppressants are prescription medicines; changes are made by transplant teams in Egypt and Europe.
- 实际监测数据
- No Egyptian registry data on withdrawal outcomes found.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Wilson 95% CI for event rates in withdrawal arm – Rejection 4/14 = 28.6% (11.7%-54.6%); DSA 5/14 = 35.7% (16.3%-61.2%) 已重新计算
- Log-symmetry of RR CIs (RR vs OR wording correct: Cochrane reports RR) – Geometric midpoints equal reported RRs (1.58, 1.41, 1.19, 0.61); consistent 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Graft rejection/loss after withdrawal of maintenance immunosuppression
- 起始等级
- 高（随机试验）
- 降级理由
- indirectness: complete withdrawal of all drugs not randomised; evidence from single-drug withdrawal
- imprecision: small CTOT-09 arm
- 升级理由
- large effect (sevenfold odds of graft failure with non-adherence; trial stopped for harm)
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- KDIGO: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients (2009) · 原始文献
Rec. 3.2: suggest that CNIs be continued rather than withdrawn (2B) and that prednisone used beyond the first week be continued rather than withdrawn (2C). Background: RCTs of complete CNI withdrawal (8 RCTs, 1891 patients) show some small benefit in graft function but significantly increased acute rejection without clear graft-survival benefit; steroid withdrawal more than 3 months after transplantation increases acute rejection. - KDIGO: Guideline landing page (Care of Kidney Transplant Recipients) (2009) · 原始文献
Confirms the 2009 guideline is the current KDIGO transplant-recipient guideline listed; no update text on the page.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | ("operational tolerance" OR "spontaneous tolerance") AND kidney transplant AND (immunosuppression withdrawal OR "drug-free") | 支持性证据 | 709 | |
| Europe PMC | 2026年10月26日 | (immunosuppression withdrawal OR "tacrolimus withdrawal" OR "calcineurin inhibitor withdrawal") AND kidney transplant AND (rejection OR "donor-specific antibod*") AND (randomized OR trial) | 反对性证据 | 12115 | |
| Europe PMC | 2026年10月26日 | (steroid withdrawal OR steroid avoidance) AND kidney transplant AND "Cochrane Database Syst Rev" | 双向 | 146 | |
| PubMed | 2026年10月26日 | tacrolimus withdrawal immune quiescent kidney transplant | 反对性证据 | 1 | |
| PubMed | 2026年10月26日 | operationally tolerant kidney transplant recipients immunosuppression discontinuation cohort | 支持性证据 | 0 | |
| Europe PMC | 2026年10月26日 | TITLE:"operationally tolerant" AND kidney | 支持性证据 | 8 | |
| Europe PMC | 2026年10月26日 | (nonadherence OR non-adherence) AND immunosuppress* AND kidney transplant AND (graft loss OR graft failure) AND (cohort OR systematic review) AND PUB_YEAR:[2015 TO 2026] | 反对性证据 | 3309 | |
| PubMed | 2026年10月26日 | natural history of clinical operational tolerance after kidney transplantation | 支持性证据 | 5 | |
| KDIGO website | 2026年10月26日 | https://kdigo.org/guidelines/transplant-recipient/ (guideline page and full PDF) | 指南 | 1 | |
| Europe PMC | 2026年10月26日 | kidney transplant AND "operational tolerance" AND (prevalence OR "natural history" OR registry) | 支持性证据 | 178 |
待解决的问题
Biomarkers that could identify the rare operationally tolerant recipient.
核查深度如何？
6 项相关研究：0 项核查了全文（其中 0 项进行了结构化偏倚风险评估），6 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 错误 (中)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 错误 (中)
New randomised (CTOT-09) and Cochrane 2026 evidence and the KDIGO full text strengthen the existing verdict and explain the reported GFR rise as a known CNI-withdrawal effect. Complete withdrawal has still not been randomised, so certainty stays moderate.
新来源: I-SRC-101 I-SRC-102 I-SRC-118
通俗解释
Elawady 医生描述了一位肾移植患者，说他停用了该患者的抗排斥药物，六周后肾脏工作得更好了。单个病例无法核实，而且六周时间太短了。研究表明，不服用抗排斥药物的人失去新肾的可能性要大得多。医生有时可以停用可的松，但前提是其他抗排斥药物继续使用。全部停用是有风险的。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (3)
-
Skipping transplant drugs often leads to losing the kidney
Butler JA et al.. Transplantation 2004 · PMID 15021846 · DOI 10.1097/01.tp.0000110408.83054.88Meta分析独立交叉核查已核查摘要★ 关键研究Not taking immunosuppressants was linked to about seven times higher odds of graft failure.
Nonadherence raises graft failure about sevenfold.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure impact of nonadherence
- 研究是如何开展的？
Systematic review
- 研究了多少人、动物或样本？
36 studies
- 实际发现了什么？
Nonadherence common; strongly linked to graft loss
- 观察到的效应有多大？
about 7-fold odds of graft failure
- 研究结果对日常生活意味着什么？
Transplant medicines protect the new kidney; stopping them is a major cause of losing it.
- 该研究有哪些局限？
Self-report measures; abstract only
- 它对 Elawady 的具体说法说明了什么？
Contradicts stopping immunosuppression.
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Cannot predict the outcome for one individual patient.
-
International guideline for kidney-transplant care
KDIGO Transplant Work Group. Am J Transplant 2009 · PMID 19845597 · DOI 10.1111/j.1600-6143.2009.02834.x指南 / 立场声明独立交叉核查已核查摘要Gives recommendations on immunosuppression and monitoring after kidney transplant.
Immunosuppression is part of standard care.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Guide transplant care
- 研究是如何开展的？
GRADE guideline
- 研究了多少人、动物或样本？
not applicable
- 实际发现了什么？
Recommendations on immunosuppression
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Anti-rejection treatment and monitoring are standard after a kidney transplant.
- 该研究有哪些局限？
Abstract only
- 它对 Elawady 的具体说法说明了什么？
Contradicts stopping all immunosuppression.
- 研究结果是否适用于德国和欧洲？
High
-
Stopping tacrolimus after kidney transplant caused rejection
Hricik DE et al.. J Am Soc Nephrol 2015 · PMID 25925687 · DOI 10.1681/ASN.2014121234随机对照试验独立交叉核查已核查摘要★ 关键研究In a trial of carefully selected low-risk patients, stopping tacrolimus led to rejection in 4 of 14 and new antibodies in 5 of 14; the trial was stopped.
Withdrawal of only tacrolimus in lowest-risk patients caused rejection or antibodies in about a third.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test whether low-risk kidney recipients can stop tacrolimus
- 研究是如何开展的？
Randomised trial
- 研究了多少人、动物或样本？
Living-donor recipients; 14 in the withdrawal arm
- 实际发现了什么？
High rates of rejection and donor-specific antibodies
- 观察到的效应有多大？
4/14 rejection; 5/14 new antibodies
- 研究结果对日常生活意味着什么？
Even stopping one anti-rejection drug can damage the kidney
- 该研究有哪些局限？
Small; stopped early
- 它对 Elawady 的具体说法说明了什么？
Contradicts stopping all immunosuppression
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Long-term graft loss rates (trial stopped)
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (3)
-
Stopping steroids early after transplant, while keeping other drugs
Woodle ES et al.. Ann Surg 2008 · PMID 18936569 · DOI 10.1097/SLA.0b013e318187d1da随机对照试验独立交叉核查已核查摘要With continued tacrolimus and MMF, early steroid withdrawal gave similar 5-year graft survival but more mild rejection.
Steroid withdrawal possible with continued immunosuppression.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test early steroid withdrawal
- 研究是如何开展的？
Blinded RCT
- 研究了多少人、动物或样本？
386 recipients
- 实际发现了什么？
Similar graft survival; more mild rejection; better metabolic profile
- 观察到的效应有多大？
rejection 17.8% vs 10.8%
- 研究结果对日常生活意味着什么？
Doctors can sometimes drop cortisone after transplant, but the other anti-rejection drugs stay.
- 该研究有哪些局限？
Selected patients; abstract only
- 它对 Elawady 的具体说法说明了什么？
Partly supports dropping cortisone; contradicts stopping all immunosuppressants.
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Cannot conclude that all immunosuppression can be stopped.
-
Stopping steroids after a kidney transplant while other anti-rejection drugs continue
Oliveras L et al.. Cochrane Database Syst Rev 2026 · PMID 42187003 · DOI 10.1002/14651858.CD005632.pub4Meta分析独立交叉核查已核查摘要★ 关键研究Across 53 trials, stopping or avoiding steroids did not clearly change graft loss in the first year; avoiding steroids slightly raised acute rejection in some regimens.
Supports steroid withdrawal only when other immunosuppressants continue; does not support stopping all drugs.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Find out whether steroids can be left out after a kidney transplant
- 研究是如何开展的？
Cochrane review of randomised trials
- 研究了多少人、动物或样本？
53 trials, 8317 recipients
- 实际发现了什么？
Similar short-term graft survival; more acute rejection with steroid avoidance unless combined with modern drugs; less post-transplant diabetes
- 观察到的效应有多大？
BPAR RR 1.58 (avoidance); graft loss RR 1.19 (withdrawal, CI 0.72-1.96)
- 研究结果对日常生活意味着什么？
Doctors can sometimes stop cortisone, but only while other anti-rejection drugs continue
- 该研究有哪些局限？
Low certainty; mostly unblinded trials
- 它对 Elawady 的具体说法说明了什么？
Supports only steroid withdrawal under specialist care, not stopping all drugs
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Whether stopping all anti-rejection drugs is safe (not studied)
-
A few kidney recipients keep working kidneys without drugs
Brouard S et al.. Am J Transplant 2012 · PMID 22974211 · DOI 10.1111/j.1600-6143.2012.04249.x病例系列 / 病例报告独立交叉核查已核查摘要27 rare patients had stable kidneys off drugs, but almost a third later lost function slowly.
Rare operational tolerance exists, but the cohort counts only successes and 30% later deteriorated.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Describe patients who tolerate a kidney without drugs
- 研究是如何开展的？
Comparison of a rare cohort with other patients
- 研究了多少人、动物或样本？
27 tolerant patients
- 实际发现了什么？
Most kept function for years; 30% slowly deteriorated
- 观察到的效应有多大？
19/27 stable at mean 9 years
- 研究结果对日常生活意味着什么？
Such cases exist but are rare and cannot be predicted
- 该研究有哪些局限？
Only successes counted
- 它对 Elawady 的具体说法说明了什么？
A rare exception, not a basis for stopping drugs
- 研究结果是否适用于德国和欧洲？
European data
- 从该研究中明确不能得出什么结论？
How many people who stop drugs keep their kidney
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Transplant centres in Europe follow KDIGO-type guidance; changes in immunosuppression are made by the transplant team.
埃及
The same applies in Egypt; graft loss means a return to dialysis.
在我的国家适用什么？
一般科学评估
错误 肾移植后停用所有抗排斥药物并不是成功：试验表明，即使只停用一种关键药物也会引起排斥反应，而 GFR 的短期升高是一种预期的药物效应。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review.. Butler JA et al.. Transplantation 2004 · PMID 15021846 · DOI 10.1097/01.tp.0000110408.83054.88
- KDIGO clinical practice guideline for the care of kidney transplant recipients.. KDIGO Transplant Work Group. Am J Transplant 2009 · PMID 19845597 · DOI 10.1111/j.1600-6143.2009.02834.x
- Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients.. Hricik DE et al.. J Am Soc Nephrol 2015 · PMID 25925687 · DOI 10.1681/ASN.2014121234
- A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.. Woodle ES et al.. Ann Surg 2008 · PMID 18936569 · DOI 10.1097/SLA.0b013e318187d1da
- Steroid avoidance or withdrawal for kidney transplant recipients.. Oliveras L et al.. Cochrane Database Syst Rev 2026 · PMID 42187003 · DOI 10.1002/14651858.CD005632.pub4
- The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases.. Brouard S et al.. Am J Transplant 2012 · PMID 22974211 · DOI 10.1111/j.1600-6143.2012.04249.x